TWIST2 Antibody

1. Research indicates that the S18-2 protein induces epithelial to mesenchymal cell transition through the TWIST2/E-cadherin signaling pathway, consequently leading to CXCR4-mediated migration of prostate cancer cells. PMID: 29396484
2. TWIST2 induces the expression of miR-221-3p, subsequently suppressing its direct target, THBS2, in lymphatic metastasis cervical cancer. PMID: 29242498
3. Epithelial membrane protein 3, a downstream effector of TWIST1/2, plays a role in inducing epithelial-to-mesenchymal transition in gastric cancer. Upregulation of epithelial membrane protein 3 might be associated with gastric cancer metastasis and serves as a potential indicator of unfavorable overall survival and progression-free survival in gastric cancer patients. PMID: 28718375
4. Findings suggest that HIF-2alpha promotes epithelial-mesenchymal transition in pancreatic cancer by regulating Twist2 binding to the promoter of E-cadherin. PMID: 26842802
5. A homozygous missense mutation in the TWIST2 gene was identified in 3 siblings affected by Setleis syndrome. This mutation alters the bHLH domain and is predicted to lead to a loss of transcription factor function due to protein substitution. PMID: 25410422
6. TWIST2 regulates epithelial-mesenchymal transition by depleting the epithelial cell phenotype of E-cadherin and promoting the mesenchymal cell phenotype with Vimentin, potentially contributing to the progression and prognosis of ovarian cancer. PMID: 27048119
7. MACC1 promotes vasculogenic mimicry in gastric cancer by regulating the HGF/c-Met-TWIST1/2 signaling pathway. PMID: 25895023
8. In patients without duplication/triplication of the 1p36.22p36.21 region and no mutations in TWIST2, mutations may exist in one of the 30 genes within this region or in other unidentified genes at different locations. PMID: 25728400
9. Data suggest that TWIST1 and, to a lesser extent, TWIST2 expressed within the tumor stroma could contribute to the epithelial-mesenchymal transition (EMT)-like tumor budding phenotype in colorectal cancers. PMID: 25528769
10. A substituted lysine at TWIST2 residue 75 results in Ablepharon Macrostomia Syndrome, while a glutamine or alanine substitution yields Barber-Say Syndrome. PMID: 26119818
11. Results show that Twist2 expression gradually increases during the progression from normal cervical squamous epithelium to cervical intraepithelial neoplasia (CIN) and cervical squamous cell carcinoma. PMID: 25420506
12. Data have identified a novel TWIST2-p21 axis that regulates the cell cycle of both normal and leukemic hematopoietic cells, implicating TWIST2 as a potential tumor suppressor in human acute myeloid leukemia. PMID: 25088197
13. TWIST1 and TWIST2 are expressed in skeletal muscle and remain unchanged in metabolic diseases. PMID: 25663706
14. Twist2 plays roles in osteogenesis differentiation, tumor formation, and epithelial-mesenchymal transition. [review] PMID: 25608809
15. LPS promotes PDCD4 degradation via a pathway involving PI3K and mTOR, releasing Twist2, which induces IL-10 via c-Maf. PMID: 24982420
16. Twist2 is the key Twist isoform linking aberrant signals from epithelial-mesenchymal transition (EMT) to senescence, making it a significant candidate biomarker for cervical cancer prognosis. PMID: 24974259
17. Nuclear beta-catenin accumulates in Twist2-induced EMT cells to facilitate ovarian cancer invasion and metastasis. PMID: 24244294
18. Research highlights a pivotal role for miR-138 in regulating colorectal cancer metastasis by targeting TWIST2. PMID: 24171926
19. Data indicate that the expression of Twist2 and Runx2 differs significantly in mesenchymal stromal cells from bone marrow (bmMSC) compared to MSC from term placenta (pMSC). PMID: 23763516
20. The identification of the Twist2-CD24 signaling pathway provides a potential therapeutic approach to target cancer stem cells in HCCs. PMID: 24193512
21. Heterogeneous expression of Twist2 in breast tumors might have a functional link to tumor progression. PMID: 23133563
22. Elevated expression of TWIST2 can contribute to invasion and metastasis of adenoid cystic carcinoma (ACC), and there might be a correlation between the hypoxic microenvironment and epithelial-mesenchymal transition in ACC. PMID: 22103974
23. This study suggests a dual role for epigenetic inactivation of TWIST2 in acute lymphoblastic leukemia, initially by altering cell growth and survival properties and subsequently by increasing resistance to chemotherapy. PMID: 22058208
24. Upregulation of TWIST2 is correlated with poor differentiation grade and shorter survival, identifying a subset of node-positive oral cavity/pharynx cancer patients with very poor prognosis. PMID: 22201613
25. Twist1 and Twist2 modulate ATF4-dependent transcriptional activity in response to Parathyroid hormone. PMID: 21866569
26. Mexican-Nahua siblings with facial and ophthalmologic features of FFDD type III were evaluated. Genomic DNA was isolated for sequencing of the TWIST2 gene. The affected siblings were homozygous for a novel TWIST2 frameshift mutation, c.168delC (p.S57AfsX45). PMID: 21931173
27. TWIST2 overexpression was linked to cervix cancer progression, making it a promising marker for determining metastatic potential. PMID: 22018873
28. Overexpression of Twist2 may contribute to breast cancer progression by activating the epithelial to mesenchymal transition program and enhancing the self-renewal of cancer stem-like cells. PMID: 21602879
29. Research suggests that the C-terminal domain of TWIST2, which is missing in the Q119X mutant form of TWIST2, is responsible for proper transactivation of the periostin gene. PMID: 21801849
30. A study correlates reduced TWIST2 and OPG expression with increased osteocalcin levels, linking altered bone remodeling to energy homeostasis in hereditary HGPS. PMID: 21738662
31. Findings implicate dermo1 as a tumor suppressor gene and a valuable molecular marker for human cancer. PMID: 21109964
32. Recessive mutations in TWIST2 cause focal facial dermal dysplasias, while dominant mutations in TWIST1 cause Saethre-Chotzen craniocynostosis, suggesting that they function independently in skin and bone development. PMID: 20691403
33. Increased expression in T-cells is associated with resistance to apoptosis and tumor progression. PMID: 19937140
34. Epigenetic silencing of TWIST2 in mutated Ig V(H) is associated with chronic lymphocytic leukemia. PMID: 15809452
35. Findings suggest that reduced expression of TWIST suppresses the multistep process of peritoneal dissemination (detachment from the primary lesion, adhesion to MCs, and invasion of MCs). PMID: 17487558
36. Twist proteins promote malignant conversion and metastatic dissemination. PMID: 18598946
37. Hypoxic TWIST1 induction is regulated by both HIF-1 and HIF-2 proteins through distinct regulatory elements in a tissue-specific manner. PMID: 19644484

Show More

Hide All

HGNC: 20670

OMIM: 200110

KEGG: hsa:117581

STRING: 9606.ENSP00000405176

UniGene: Hs.422585